Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Unicycive Therapeutics Inc
UNCY
Healthcare
Biotechnology
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis (CKD), and UNI 494,...
for treatment of acute kidney injury (AKI). Renazorb is initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum). UNI 494 is initially developed by and licensed to it from Sphaera Pharmaceuticals, respectively.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:UNCY)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 31, 2023 7:00am
New Press Release - Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
Closed transformational fundraise that included $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestonesFinancing by new and existing institutional investors from high-profile healthcare-focused funds to support launch and commercialization of...
read article.
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 10, 2023 1:25pm
UNCY....flirting with VWAP
Cheers !
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 10, 2023 12:44pm
UNCY .... thru RBL at $2.63.... on watch still
it better get going.....Me no position
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 10, 2023 10:37am
UNCY.....now right in the "thick of res"....$2.50
N>H>O>D.......... All looks good...could go way higher.... I don't know ; ) I just want to say that.... Stops save Portfolios Cheers !
(63)
•••
Iseneschal
X
Comment by
Iseneschal
on Mar 10, 2023 9:07am
RE:UNCY .....The trend continues....Day 6 of run....Sheesh
I failed to mention that my chart tells me there congestion at this level.....resistance start at ~ $2.32 Cheers
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 10, 2023 9:04am
UNCY .....The trend continues....Day 6 of run....Sheesh
Close Prices Last 3 Months Price/volumes not adjusted for restructures Date Ex Sym Open High Low Close Chg
...more
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 09, 2023 7:38am
UNCY....ripping in the pre-market open
Volume & price action no position Cheers !
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 07, 2023 9:25am
UNCY...... Oops...my last 2 posts were meant for TRKA
LoL
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 07, 2023 9:16am
TRKA ....hmmm all that Rev and still an increase in Net Loss
mainly due to Interest expense was huge....must be a lot of debt.....would it be to the acquisitions See how this plays out No position
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 07, 2023 9:12am
TRKA .... ER news
Troika Media Group Inc. Reports Record Revenue of $187.9 million, Adjusted EBITDA of $5.0 million for the Six Months Ended December 31, 2022 Tue Mar 07 09:10:09 2023 EDT Troika Media
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 07, 2023 9:00am
New Press Release - The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
(NewsDirect)By Julian Richard, BenzingaUnicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company spearheading efforts to develop effective, safe, and novel treatments for kidney disease to improve patient and caregiver quality of life due to kidney failure. Its candidate UNI-494 is...
read article.
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 07, 2023 7:56am
UNCY........up in PM trading...at $1.37
On watch No position
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 06, 2023 2:29pm
UNCY.....dodged a bullet there ; )
UNCY halted on the way down....seldom a "good thing" GLTA
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 06, 2023 2:18pm
UNCY ...... I'd say it will go higher ; )
I sold mine I like leaving some profit for the next guy Cheers !
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 06, 2023 2:17pm
UNCY...Breaks $1.43 on that pop
With a volume spike Sold ; )
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Positive PEA Announced for Proposed Lithium Mining Operation in Ontario
814 gpt Silver Over 1.0 M Within 6 Meters of 435 gpt and 174 gpt Over 22 M at Columba Silver Project
Emperor Metals Intersects Near Surface Mineralization; Building Bulk Tonnage Open Pit Potential at Duquesne West Gold Project in Quebec
New Images for the Passive Seismic Survey Very Promising for the Topaz Helium Project in Minnesota
Learn How a Pharma R&D Company Can De-Risk Your Healthcare Portfolio
POET Technologies Issues Letter to Shareholders
Silver is Considered a Safe Haven Asset But the White Metal Has Far More to it Than Meets the Eye
NexOptic Begins Announcing New Team Additions
AI Alchemy: Turning Data into Gold with Artificial Intelligence